Lulizumab pegol

Last updated

Lulizumab pegol
Monoclonal antibody
Type ?
Source Humanized
Target glycoprotein CD28
Clinical data
Other namesBMS-931699
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
Chemical and physical data
Formula C552H859N149O164S4
Molar mass 12335.06 g·mol−1

Lulizumab pegol (INN; [1] development code BMS-931699) is a monoclonal antibody developed by Bristol-Myers Squibb for the treatment of autoimmune diseases [2] such as cutaneous lupus erythematosus. [3]

References

  1. ↑ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
  2. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council - Lulizumab Pegol]" (PDF). American Medical Association .
  3. ↑ Kuhn A, Landmann A, Wenzel J (July 2016). "Advances in the treatment of cutaneous lupus erythematosus". Lupus. 25 (8): 830–837. doi:10.1177/0961203316641771. PMID   27252259.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.